Danaher Co. (NYSE:DHR) Director Donald J. Ehrlich sold 10,578 shares of the stock in a transaction that occurred on Tuesday, October 23rd. The stock was sold at an average price of $95.77, for a total transaction of $1,013,055.06. Following the sale, the director now directly owns 105,491 shares of the company’s stock, valued at approximately $10,102,873.07. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
NYSE DHR opened at $97.14 on Friday. The company has a market capitalization of $69.08 billion, a price-to-earnings ratio of 24.10, a P/E/G ratio of 1.90 and a beta of 1.01. Danaher Co. has a fifty-two week low of $91.41 and a fifty-two week high of $110.13. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 18th. The conglomerate reported $1.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.03. The firm had revenue of $4.85 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Danaher had a return on equity of 11.59% and a net margin of 14.07%. Danaher’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 4.51 earnings per share for the current fiscal year.
A number of analysts recently issued reports on DHR shares. Bank of America set a $113.00 target price on shares of Danaher and gave the stock a “buy” rating in a research report on Thursday, July 19th. ValuEngine raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Thursday, July 12th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $116.00 target price for the company in a research report on Monday, July 23rd. Robert W. Baird dropped their target price on shares of Danaher from $116.00 to $114.00 and set an “outperform” rating for the company in a research report on Friday, October 19th. Finally, Morgan Stanley increased their target price on shares of Danaher from $122.00 to $126.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Danaher presently has a consensus rating of “Buy” and a consensus price target of $112.14.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its stake in shares of Danaher by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 1,915,209 shares of the conglomerate’s stock valued at $187,519,000 after buying an additional 40,320 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in shares of Danaher by 33.4% during the 1st quarter. Summit Trail Advisors LLC now owns 4,787 shares of the conglomerate’s stock valued at $269,000 after buying an additional 1,199 shares during the last quarter. Mount Yale Investment Advisors LLC purchased a new position in shares of Danaher during the 1st quarter valued at approximately $103,000. Avalon Advisors LLC boosted its stake in shares of Danaher by 0.6% during the 1st quarter. Avalon Advisors LLC now owns 109,233 shares of the conglomerate’s stock valued at $10,695,000 after buying an additional 621 shares during the last quarter. Finally, Park National Corp OH boosted its stake in shares of Danaher by 7.8% during the 2nd quarter. Park National Corp OH now owns 132,164 shares of the conglomerate’s stock valued at $13,042,000 after buying an additional 9,535 shares during the last quarter. Hedge funds and other institutional investors own 77.11% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Featured Article: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.